In memoriam Claude Bachmann 1941-2022
In: Schweizerische Ärztezeitung: SÄZ ; offizielles Organ der FMH und der FMH Services = Bulletin des médecins suisses : BMS = Bollettino dei medici svizzeri
ISSN: 1424-4004
4 Ergebnisse
Sortierung:
In: Schweizerische Ärztezeitung: SÄZ ; offizielles Organ der FMH und der FMH Services = Bulletin des médecins suisses : BMS = Bollettino dei medici svizzeri
ISSN: 1424-4004
8 páginas, 2 figuras. ; In 2015-2016, we and others reported ALDH18A1 mutations causing dominant (SPG9A) or recessive (SPG9B) spastic paraplegia. In vitro production of the ALDH18A1 product, Δ1 -pyrroline-5-carboxylate synthetase (P5CS), appeared necessary for cracking SPG9 disease-causing mechanisms. We now describe a baculovirus-insect cell system that yields mgs of pure human P5CS and that has proven highly valuable with two novel P5CS mutations reported here in new SPG9B patients. We conclude that both mutations are disease-causing, that SPG9B associates with partial P5CS deficiency and that it is clinically more severe than SPG9A, as reflected in onset age, disability, cognitive status, growth, and dysmorphic traits ; Whole‐exome sequencing analysis was funded by a "Fondazione del Monte" grant to Professor MS for clinical exome sequencing applied to the diagnosis of ultrarare/orphan inherited diseases. The Genetic Bank (Biobanca del Laboratorio di Genetica Umana IRCCS Gaslini), member of the Network Telethon of Genetic Biobanks (Project No. GTB12001), funded by Telethon Italy, provided us with specimens. VR was supported by grants of the Fundación Inocente Inocente and of the Spanish Government (MINECO BFU2017‐84264‐P). ; Peer reviewed
BASE
Abstract Urea cycle disorders (UCDs) are inborn errors of ammonia detoxification/arginine synthesis due to defects affecting the catalysts of the Krebs-Henseleit cycle (five core enzymes, one activating enzyme and one mitochondrial ornithine/citrulline antiporter) with an estimated incidence of 1:8.000. Patients present with hyperammonemia either shortly after birth (~50%) or, later at any age, leading to death or to severe neurological handicap in many survivors. Despite the existence of effective therapy with alternative pathway therapy and liver transplantation, outcomes remain poor. This may be related to underrecognition and delayed diagnosis due to the nonspecific clinical presentation and insufficient awareness of health care professionals because of disease rarity. These guidelines aim at providing a trans-European consensus to: guide practitioners, set standards of care and help awareness campaigns. To achieve these goals, the guidelines were developed using a Delphi methodology, by having professionals on UCDs across seven European countries to gather all the existing evidence, score it according to the SIGN evidence level system and draw a series of statements supported by an associated level of evidence. The guidelines were revised by external specialist consultants, unrelated authorities in the field of UCDs and practicing pediatricians in training. Although the evidence degree did hardly ever exceed level C (evidence from non-analytical studies like case reports and series), it was sufficient to guide practice on both acute and chronic presentations, address diagnosis, management, monitoring, outcomes, and psychosocial and ethical issues. Also, it identified knowledge voids that must be filled by future research. We believe these guidelines will help to: harmonise practice, set common standards and spread good practices with a positive impact on the outcomes of UCD patients. ; Development of these guidelines was financially supported by the "Guideline-Pool" from the German Metabolic Society (Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen) who received funding from Cytonet, Merck Darmstadt, Merck Serono, Orphan Europe, SHS International. The second guideline group meeting was in addition supported by Nutricia Italia, Orphan Europe and Swedish Orphan International. The third GDG meeting received additional financial and logistic support from CIBERER, Spain. The authors confirm full independence from the aforementioned sponsors who did not influence the guidelines development at any stage. JH receives support for the scientific work on UCDs from the Swiss National Science Foundation (grant 310030_127184/1). VR received support from grants BFU2008-05021 of the Spanish Ministry of Science and Prometeo/2009/051 of the Valencian Government. CDV was supported by the grant "CCM 2010: Costruzione di percorsi diagnostico-assistenziali per le malattie oggetto di screening neonatale allargato" from the Italian Ministry of Health. The clinical fellowship of DM is supported by the "Associazione la Vita è un Dono". Distribution of the guidelines is endorsed by the DGKJ (Deutsche Gesellschaft für Kinder- und Jugendmedizin) which offers support for translations. These guidelines have been adopted by and will be further developed under the umbrella of the "E-IMD" project which has received funding from the European Union, in the framework of the Health Programme. ; Peer Reviewed
BASE
Purpose: To assess how the current practice of newborn screening (NBS) for homocystinurias compares with published recommendations. Methods: Twenty-two of 32 NBS programmes from 18 countries screened for at least one form of homocystinuria. Centres provided pseudonymised NBS data from patients with cystathionine beta-synthase deficiency (CBSD, n = 19), methionine adenosyltransferase I/III deficiency (MATI/IIID, n = 28), combined remethylation disorder (cRMD, n = 56) and isolated remethylation disorder (iRMD), including methylenetetrahydrofolate reductase deficiency (MTHFRD) (n = 8). Markers and decision limits were converted to multiples of the median (MoM) to allow comparison between centres. Results: NBS programmes, algorithms and decision limits varied considerably. Only nine centres used the recommended second-tier marker total homocysteine (tHcy). The median decision limits of all centres were ≥ 2.35 for high and ≤ 0.44 MoM for low methionine, ≥ 1.95 for high and ≤ 0.47 MoM for low methionine/phenylalanine, ≥ 2.54 for high propionylcarnitine and ≥ 2.78 MoM for propionylcarnitine/acetylcarnitine. These decision limits alone had a 100%, 100%, 86% and 84% sensitivity for the detection of CBSD, MATI/IIID, iRMD and cRMD, respectively, but failed to detect six individuals with cRMD. To enhance sensitivity and decrease second-tier testing costs, we further adapted these decision limits using the data of 15 000 healthy newborns. Conclusions: Due to the favorable outcome of early treated patients, NBS for homocystinurias is recommended. To improve NBS, decision limits should be revised considering the population median. Relevant markers should be combined; use of the postanalytical tools offered by the CLIR project (Collaborative Laboratory Integrated Reports, which considers, for example, birth weight and gestational age) is recommended. tHcy and methylmalonic acid should be implemented as second-tier markers. ; This publication arises from the E-HOD project (Chafea grant no. December 2, 2012), which has received funding from the European Union, in the framework of the Health Programme. Many programmes cooperate closely with Piero Rinaldo and coworkers (Mayo Clinic, Rochester, Minnesota, USA) and wish to acknowledge the ongoing support provided by the R4S and CLIR initiatives (http://clir.mayo.edu). ; info:eu-repo/semantics/publishedVersion
BASE